Transcriptome and phospho-RTK profiling of MC38 cells have now given further insights into mechanisms of CEACAM1-mediated reduction of metastasis; we have identified that CEACAM1-L acts as a negative regulator of the EPHA2 receptor Tyr kinase, also involved in CRC progression and liver metastasis [24–26], as judged by either lower EPHA2 Tyr phosphorylation in MC38-CC1-L cells or higher pEPHA2 levels in HT29 CC1KD cells. The gene discussed is CEACAM1; the disease is colorectal carcinoma.